BiotechTube
Predicta Biosciences

Predicta Biosciences

San Diego, United States· Est.
predictabiosciences.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Predicta Biosciences is a private, venture-backed diagnostics company founded in 2018 and based in San Diego. The company has developed the GenoPredicta™ platform, a transformative cellular liquid biopsy that performs whole genome sequencing on circulating tumor cells and bone marrow samples to deliver superior sensitivity and genomic insights for multiple myeloma. With its first commercial product launched in April 2025 and a recent $23.4M funding round in October 2025, Predicta is positioned to scale its platform, challenge the current standard of care, and expand into broader hematological and autoimmune indications. The company is led by a seasoned team with deep expertise in genomics and oncology, supported by prominent scientific founders and investors.

OncologyHematology

Technology Platform

Cellular liquid biopsy platform utilizing whole genome sequencing (WGS) of circulating tumor cells (CTCs) and bone marrow cells for comprehensive genomic characterization in blood cancers.

Opportunities

The primary opportunity is to displace the outdated FISH standard in multiple myeloma with a more comprehensive, less invasive diagnostic, enabling earlier intervention and personalized therapy.
The platform's applicability to other blood cancers and autoimmune diseases presents a significant expansion runway.
The growing emphasis on minimal residual disease (MRD) monitoring creates a large, recurring testing market for blood-based surveillance.

Risk Factors

Key risks include securing adequate insurance reimbursement for a higher-cost WGS-based test and overcoming clinical inertia to change long-standing diagnostic practices.
The company also faces competition from other liquid biopsy technologies and must successfully execute the technical and commercial scaling of its complex cellular sequencing platform.

Competitive Landscape

Predicta competes with traditional FISH testing and targeted NGS panels from large diagnostic labs. In liquid biopsy, it faces competitors focused on cell-free DNA (e.g., Guardant Health, Natera) but differentiates by sequencing intact circulating tumor cells, which may provide advantages for detecting structural variants. Other companies developing CTC-based analyses exist, but Predicta's focus on whole genome sequencing and hematological malignancies is a specialized niche.

More companies in United States →